The pharmacokinetics of pamiparib in the presence of a strong CYP3A inhibitor (itraconazole) and strong CYP3A inducer (rifampin) in patients with solid tumors: an open-label, parallel-group phase 1 study

ConclusionsPamiparib plasma exposure was reduced 38 –43% with rifampin coadministration but was unaffected by itraconazole coadministration. Pamiparib dose modifications are not considered necessary when coadministered with CYP3A inhibitors. Clinical safety and efficacy data will be used with these results to recommend dose modifications when pamip arib is coadministered with CYP3A inducers.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research